[go: up one dir, main page]

MX2017013645A - Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-me tilpiperidin-4-il)-3-(4-cianofenil)urea maleato. - Google Patents

Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-me tilpiperidin-4-il)-3-(4-cianofenil)urea maleato.

Info

Publication number
MX2017013645A
MX2017013645A MX2017013645A MX2017013645A MX2017013645A MX 2017013645 A MX2017013645 A MX 2017013645A MX 2017013645 A MX2017013645 A MX 2017013645A MX 2017013645 A MX2017013645 A MX 2017013645A MX 2017013645 A MX2017013645 A MX 2017013645A
Authority
MX
Mexico
Prior art keywords
crystalline forms
methylpiperidin
cyanophenyl
benzo
urea maleate
Prior art date
Application number
MX2017013645A
Other languages
English (en)
Other versions
MX375384B (es
Inventor
Christian Hansen Eric
Scott Seadeek Christopher
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013645(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017013645A publication Critical patent/MX2017013645A/es
Publication of MX375384B publication Critical patent/MX375384B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una forma cristalina de 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1 metilpiperidin-4-il)-3-( 4-cianofenil)urea maleato y a composiciones farmacéuticas de este, a intermediarios y métodos para la producción y el aislamiento de las formas cristalinas y composiciones, y a métodos para usar dichas formas cristalinas y composiciones en el tratamiento del crecimiento celular anormal en mamíferos, en especial, seres humanos.
MX2017013645A 2015-04-24 2016-04-13 Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4-cianofenil)urea maleato. MX375384B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562152108P 2015-04-24 2015-04-24
PCT/IB2016/052107 WO2016170451A1 (en) 2015-04-24 2016-04-13 Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Publications (2)

Publication Number Publication Date
MX2017013645A true MX2017013645A (es) 2018-03-08
MX375384B MX375384B (es) 2025-03-06

Family

ID=55806563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013645A MX375384B (es) 2015-04-24 2016-04-13 Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4-cianofenil)urea maleato.

Country Status (24)

Country Link
US (4) US10414748B2 (es)
EP (2) EP3666768B1 (es)
JP (1) JP6345728B2 (es)
KR (2) KR20190038677A (es)
CN (1) CN107531667A (es)
AR (1) AR104391A1 (es)
AU (1) AU2016251940C1 (es)
BR (1) BR112017021075B1 (es)
CA (2) CA2983387C (es)
CY (2) CY1124056T1 (es)
DK (2) DK3666768T3 (es)
ES (2) ES2923593T3 (es)
HK (1) HK1243416A1 (es)
HU (2) HUE048664T2 (es)
IL (1) IL255224B (es)
MX (1) MX375384B (es)
PL (2) PL3286176T3 (es)
PT (2) PT3666768T (es)
RU (1) RU2717564C2 (es)
SG (1) SG11201707863QA (es)
SI (2) SI3286176T1 (es)
TW (1) TWI646093B (es)
WO (1) WO2016170451A1 (es)
ZA (1) ZA201706391B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2983387C (en) 2015-04-24 2022-08-16 Pfizer Inc. Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
US20230107634A1 (en) * 2020-01-28 2023-04-06 Teva Pharmaceuticals International Gmbh Processes for the preparation of glasdegib and salt thereof and solid state forms of glasdegib maleate and process for preparation thereof
EP4126237B1 (en) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
WO2023017541A1 (en) * 2021-08-12 2023-02-16 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methyl piperidin-4-yl)-3-(4-cyanophenyl)urea maleate
CN114668849B (zh) * 2021-12-31 2024-01-23 中国人民解放军军事科学院军事医学研究院 Shh通路调控生物节律及其相关应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2008001575A1 (fr) 2006-06-28 2008-01-03 Nikon Corporation Dispositif de localisation, dispositif de mise au point automatique et appareil photographique
GEP20125702B (en) * 2007-06-29 2012-12-10 Pfizer Benzimidazole derivatives
CA2983387C (en) 2015-04-24 2022-08-16 Pfizer Inc. Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

Also Published As

Publication number Publication date
RU2017137269A3 (es) 2019-09-13
AU2016251940A1 (en) 2017-10-12
AU2016251940B2 (en) 2018-08-30
ES2774053T3 (es) 2020-07-16
SG11201707863QA (en) 2017-11-29
US20190382368A1 (en) 2019-12-19
RU2717564C2 (ru) 2020-03-24
CN107531667A (zh) 2018-01-02
HK1243416A1 (zh) 2018-07-13
EP3666768A1 (en) 2020-06-17
US20180086731A1 (en) 2018-03-29
PT3286176T (pt) 2020-02-24
CA2983387C (en) 2022-08-16
TWI646093B (zh) 2019-01-01
IL255224B (en) 2021-01-31
ES2923593T3 (es) 2022-09-28
MX375384B (es) 2025-03-06
JP6345728B2 (ja) 2018-06-20
US10414748B2 (en) 2019-09-17
CY1125333T1 (el) 2025-03-28
BR112017021075B1 (pt) 2021-08-03
HUE059506T2 (hu) 2022-11-28
AU2016251940C1 (en) 2019-04-11
DK3666768T3 (da) 2022-06-27
US11891372B2 (en) 2024-02-06
ZA201706391B (en) 2020-12-23
SI3666768T1 (sl) 2022-09-30
SI3286176T1 (sl) 2020-04-30
US11891373B2 (en) 2024-02-06
WO2016170451A1 (en) 2016-10-27
AR104391A1 (es) 2017-07-19
TW201702238A (zh) 2017-01-16
KR20190038677A (ko) 2019-04-08
HUE048664T2 (hu) 2020-07-28
CA2927736A1 (en) 2016-10-24
EP3286176B1 (en) 2020-01-15
CA2983387A1 (en) 2016-10-27
JP2016204373A (ja) 2016-12-08
NZ735719A (en) 2020-11-27
PL3286176T3 (pl) 2020-11-30
CY1124056T1 (el) 2022-03-24
PL3666768T3 (pl) 2022-09-19
US20220024893A1 (en) 2022-01-27
US11168066B2 (en) 2021-11-09
KR102078444B1 (ko) 2020-02-17
EP3666768B1 (en) 2022-06-15
PT3666768T (pt) 2022-07-22
EP3286176A1 (en) 2018-02-28
US20220024894A1 (en) 2022-01-27
IL255224A0 (en) 2017-12-31
DK3286176T3 (da) 2020-03-02
BR112017021075A2 (pt) 2018-07-03
RU2017137269A (ru) 2019-05-24
KR20170129245A (ko) 2017-11-24

Similar Documents

Publication Publication Date Title
MX2017013645A (es) Formas cristalinas de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-il)-1-me tilpiperidin-4-il)-3-(4-cianofenil)urea maleato.
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
MX2019007080A (es) Compuestos de benzimidazol como inhibidores de c-kit.
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MX377545B (es) Macrociclos con grupos p2' heterocíclicos como inhibidores del factor xia.
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
PE20181919A1 (es) Amidas heterociclicas utiles como moduladores de proteinas
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
CO2018007738A2 (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
PE20171737A1 (es) Derivados de quinazolinona biciclicos
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
ECSP12012201A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
PE20180036A1 (es) Inhibidores de bromodominio
BR112018009745A2 (pt) compostos heterocíclicos para o tratamento de doença
MX2019001225A (es) Compuesto aromatico heterociclico nitrogenoso, metodo de preparacion del mismo, composicion farmaceutico del mismo y aplicacion del mismo.
CL2018003109A1 (es) Formas polimorficas de 3-[2-butil-1-(2-dietilamino-etil-1h-benzoimidazol-5-yl]-n-hidroxi-acrilamida y sus usos.
EA201892235A1 (ru) Гранулированная композиция для перорального применения
CL2012001606A1 (es) Compuestos derivados de tiazoles bicíclicos como moduladores alostéricos de receptores mglur5; composición farmacéutica que los comprende; procedimiento de preparación de la composición farmacéutica; combinación farmacéutica; y uso del compuesto en la prevención, tratamiento o profilaxis de trastornos neurológicos o psiquiátricos.
HUE058049T2 (hu) Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására
ECSP17000222A (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer
BR112016012625A8 (pt) Forma de sal cristalino de (s)-(2-(6-cloro-7- metil-1h-benzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5- metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona como antagonista receptor de orexina

Legal Events

Date Code Title Description
FG Grant or registration